A cute upper gastrointestinal bleeding (AUGIB) remains one of the most emergent and potentially fatal medical cases that require hospitalization and careful monitoring of the patients. Bleeding may be caused by many different lesions of variable prognostic importance. Peptic ulcer and varices are the main and more significant causes of AUGIB. Approximately, 45% to 60% of admissions for AUGIB worldwide are due to peptic ulcers. [1] [2] [3] [4] [5] During the past years major advances in the diagnostic and therapeutic approaches have been achieved, mainly in peptic ulcer disease, cirrhosis, and portal hypertension. [6] [7] [8] The available guidelines for the management of peptic ulcers and prevention of bleeding in patients with portal hypertension are thought to offer better handling of these common diseases.
9,10 Eradication of Helicobacter pylori, the offending agent for ulcer formation, has changed the natural history of peptic ulcer disease and has led to a reduction in ulcer recurrences and complications, especially bleeding. On the other hand, the population is aging and due to coexisting illnesses the need for nonsteroidal anti-inflammatory drugs (NSAIDs) consumption in these patients is increasing, with a parallel increase in bleeding complications. stable, despite the improved diagnostic and therapeutic approaches that are available for preventing and managing AUGIB.
The aim of this study was to compare the epidemiologic characteristics and the clinical outcome of patients presenting with AUIGB between 2 distinct 1-year periods during the past 10 years in our area.
PATIENTS AND METHODS
We prospectively evaluated data from patients admitted to the hospital with AUGIB in a defined geographical area of our country (Achaia prefecture) in 1-year period of time, from January to December 2005. We compared these data with retrospectively collected data in the same population 10 years ago, from January to December of 1995, as follows.
All patients with AUGIB, being over 16 years of age and residents in our area, who were admitted in all 3 regional hospitals (1 university and 2 nonuniversity ones) were included in our study. Nonresident patients hospitalized with AUIGB were excluded. We also included the bleeding episodes of the upper gastrointestinal (GI) tract that occurred in already hospitalized patients (inpatients). AUGIB was diagnosed when hematemesis, bloody nasogastric aspiration, or melena and other clinical or laboratory evidence of acute blood loss from the upper GI tract were present.
The estimated incidence of the AUGIB and peptic ulcer bleeding (PUB) was calculated using data from the population of this area according to the National Statistical Service of Greece Data in the years 1995 (period A) and 2005 (period B), respectively. According to these data, the population of this selected area was 300,078 and 326,794 in the years 1995 and 2005, respectively. The incidence was also adjusted to age, by calculating the number of the patients in a specific age group using also the same demographic official data.
It is important to mention that during the 2 periods the management of bleeding patients was in general the same. Injection hemostasis was the first line treatment for PUB in both periods, although use of mechanical clips and the application of thermal devices such as argon plasma coagulation were added to adrenaline injection in some patients in period B. In patients with esophageal variceal bleeding band ligation was more widely used in the latter period instead of sclerotherapy. Endoscopic injection hemostasis with histoacryl was performed to patients with fundic variceal bleeding. According to the general practice, emergency endoscopy was performed in the first 24-hour of admission in the majority of patients, or immediately after resuscitation in patients with massive bleeding in both periods. In both periods, video endoscopes were used. The medical treatment was also the same in the 2 periods, consisting of proton pump inhibitors (PPIs) given intravenously in usual doses for all patients. Higher doses of PPIs were not used in any period. Somatostatin IV for 5 days was added to endoscopic treatment in patients with variceal bleeding in both periods.
Demographic and clinical characteristics of the patients were recorded. The collection of these data was made in the same way for both periods. Each patient's age, sex, recent consumption of NSAIDs, oral anticoagulants and antiplatelet drugs, laboratory tests (hemoglobulin, urea) and the presence of shock during admission, coexisting illnesses, endoscopic diagnoses, and clinical outcome were registered in standarized database categories. Shock was defined as systolic blood pressure less than 100 mm Hg and a pulse rate of more than 100 beats/min. Coexisting illnesses were encountered as follows. The patients were separated in 3 categories, depending on the condition of the patient in the admittance. We categorized as stage 1 patients with no serious illnesses (hypertension, endocrine, orthopedic diseases, etc), in a rather good condition. As stage 2, we categorized patients with illnesses who need more careful monitoring than those in stage 1, as they ran the risk of destabilization (diabetes mellitus, cardiac problems, compensated cirrhosis, cancer in a stabilized condition), and finally we referred to stage 3 patients as those suffering from major health problems (such as recent myocardial infarction, decompensated cirrhosis, cancer with metastases). Stigmata of active or recent bleeding were classified according to the Forrest Classification: Forrest Ia: active spurting bleeding; Ib: active oozing bleeding; IIa: nonbleeding visible vessel; IIb: adherent clot; IIc: spots, a nonbleeding visible vessel was defined as a raised red spot resistant to washing.
The clinical outcomes were analyzed according to the duration of hospitalization, the number of transfused blood units per patient, the rate of rebleeding, the need for emergency surgical hemostasis, and mortality defined as death within the hospitalization period.
Statistical Analysis
Continuous variables were expressed as mean ± standard deviation and were compared by using Student t test. Categorical variables were expressed as percentages and differences between groups were tested for significance by using the w 2 test. To define changes in incidence rate of AUGIB and PUB we estimated rates with 95% confidence interval (CI) by Poisson regression models, a member of the family of generalized linear models. The number of events (ulcer only or combined with AUGIB) grouped by period, patient sex, and age group was used as the response variable, using the natural logarithm of the population size as the offset variable. Estimation of Poisson regression model parameters was made with the ''glm'' procedure of the R (version 2.1.1) environment for statistical computing and graphics. All other analyses were performed with the Statistical Package for the Social Sciences (SPSS) version 13 (SPSS Chicago, IL).
RESULTS

Incidence of AUGIB
A total number of 353 patients (256 males and 97 females) with AUGIB were hospitalized during the year 2005 (period B) whereas during 1995 (period A) the patients who needed hospitalization for upper GI bleeding in the same area were 489 (364 males and 125 females). We observed a statistically significant reduction in the incidence of AUGIB from 162.9 cases/100,000 population to 108.3 cases/100,000 population (rate ratio = 0.49, CI 95% = 0.37-0.63) ( Table 1 , Fig. 1 ).
Incidence of PUB/Other Causes
During the former period (A) 314 patients admitted with PUB, giving an overall incidence of 104.8 cases/ 100,000 population, whereas in the later period (B) the incidence of PUB in the same area was 72.5 cases/100,000 population (rate ratio = 0.49, CI 95% = 0.35-0.67) ( Table 1, Fig. 2 ). This reduction was mainly due to the reduction in the incidence of duodenal ulcer bleeding from 66.7 cases/100,000 to 35.5/100,000 population). Gastric ulcer bleeding incidence remained unchanged (34.4/100,000 vs. 31.3/100,000). We did not notice any statistically significant difference in the incidence of variceal bleeding (6.6/100,000 in 2005 vs. 6.4/100,000 in 1995) or other causes of bleeding ( Table 2) .
Age of Bleeding Patients
Patients are older in the later period with a mean age 66.1 ± 16.1 years in period B versus 59.4 ± 17.1 years in period A, P<0.0001 (Table 4 ). The increased age is attributed to the statistically increased incidence of both AUGIB and PUB in patients over 75 years in the later period according to our statistical model (CI 95% = 1.93-4.21 in AUGIB and CI 95% = 1.57-4.24 in bleeding peptic ulcers) ( Table 1, Fig. 3 ).
Coexisting Illnesses
The percentage of patients with coexisting diseases was higher in the later period (B) in comparison to period A. In 1995, 30.9% of patients did not have other health problems versus 21.8% of the bleeding patients in 2005, P = 0.003. On the contrary, in period B there was an increase (15%) in patients with serious comorbid problems (stage 3) versus 10.3% in period A, P = 0.036 (Table 3 ).
Drugs
The percentage of patients taking NSAIDs before the bleeding episode was not different between the 2 periods (49.3% in period A vs. 48.2% in period B, ns), whereas a remarkable increase was noticed in the use of both antiplatelet drugs (10.7% vs. 2.1% of the patients, P<0.0001) and oral anticoagulants (warfarin) (6.7% vs. 1% of patients, P = 0.001) throughout the 10-year period. The combined use of NSAIDs and oral anticoagulant drugs was also increased (2.5% vs. 0.6% of patients, P = 0.02) ( Table 3) .
Clinical Outcome
Blood transfusion requirements per patient were significantly lower (2 ± 2.4 vs. 2.5 ± 2 in periods B and A, respectively, P = 0.009) ( Table 4 ). There was also a statistically significant difference in the mean hospitalization days in the 2 periods (6.9 ± 5.1 d in 2005 vs. 6 ± 3.8 d in 1995, P = 0.01).
We observed a statistically significant reduction in the rate of rebleeding in patients with PUB after an initial period of clinical stability (5.9% vs. 12%, P = 0.014 in period B and A, respectively) and the surgical hemostasis for continuing or recurrent bleeding (3% vs. 5.9%, P = 0.001 in 2005 vs. 1995).
Although an increased mortality rate was observed recently this increase did not reach a statistically significant level (6.5% in year 2005 vs. 3.9% in 1995). Mortality in the subgroup of patients with PUB remained unchanged (4.2% in period B vs. 3.2% in period A).
DISCUSSION
This study demonstrates changes in the incidence and clinical characteristics of AUGIB between 2 distinct periods, a decade apart, in patients coming from a defined geographic area. A 33.6% decrease was observed in the incidence of AUGIB. This reduction was mainly due to the parallel reduction in the incidence of bleeding peptic ulcers (30.8%). More pronounced decrease was observed in the incidence of duodenal ulcer bleeding (46.7%) whereas the incidence of gastric ulcer bleeding remained unchanged. A 23% decrease in the incidence of AUGIB in 6.5-year period in the Amsterdam area was also observed in a recent study by van Leerdam et al, 15 but in this study although a decrease in the incidence of duodenal ulcer bleeding was observed this reduction did not reach a statistically significant level. The reduction in the incidence of duodenal ulcer bleeding could be attributed to the reduction of new cases of duodenal ulcer patients, the better management of patients with chronic duodenal ulcers, and the prevention of NSAIDs-related ulcer bleeding.
Several epidemiologic studies worldwide have shown that the incidence of uncomplicated duodenal ulcers has been reduced in the last years. [16] [17] [18] This reduction has been attributed to the decline in the prevalence of H. pylori infection, the main agent responsible for duodenal ulcer formation. [17] [18] [19] A low acquisition rate of the organism because of an improvement in the socio-sanitary conditions is responsible for this change. Also almost inevitable exposure to antibiotics during childhood and adolescence may be another contributing factor and the widespread use of H. pylori eradication therapy at the present time. 20 Nowadays, the trend is to eradicate H. pylori right at its detection, even in the absence of a peptic ulcer, in a positive CLO test or in biopsies taken in a gastroscopy or even after the measurement of antibodies against Helicobacter or in a breath test examination. 1, 21, 22 The reduction of the burden of duodenal ulcer disease is an additional factor. Eradication of H. pylori, which can be achieved in over 90% of patients with peptic ulcer, reduces ulcer recurrences as well as ulcer bleeding and rebleeding rates in these patients. 21, 22 Also prevention of peptic ulcer formation and bleeding in patients taking NSAIDs adds to this reduction. Although the population is aging and the range of indications for aspirin or NSAIDs is increasing we did not observe an increase in the use of NSAIDs in the patients presented with AUGIB. Incidence of bleeding from gastric ulcers which in contrast to duodenal ulcers are more likely associated with NSAID use than with H. pylori infection remained unchanged in our study. Probably the general population receives more NSAIDs nowadays in comparison with the last decade, but they are more carefully prescribed according to current guidelines. 23 Widespread gastroprophylaxis with PPIs in current doses especially in high risk patients and treatment with the minimum effective dose of indicated NSAIDs (such as prophylaxis for ischemic disease) seems to have been used more often during the last years. In a recently published British study, increased prescriptions for NSAID by about 13% and aspirin 75 mg by 460% between 1990 and 1999 has been reported in the general population. 24 More recently, the increased use of safer COX-2 selective inhibitors, which have been associated with significantly fewer gastroduodenal lesions and complications, may be an additional factor in decreasing the chance of developing bleeding. 25 On the other side, we observed an increased use of oral anticoagulants and other antithrombotic drugs among patients with AUGIB recently and probably this trend will increase in the future due to increasing use of oral anticoagulants or antiplatelet drugs in a variety of diseases, especially in elderly population. In a recent study, oral anticoagulants prescription has been increased by 200%, from 1990 to 1999 in England. 23 Rebleeding and emergency surgical hemostasis in PUB patients has been reduced recently in comparison with the previous period. More efficient endoscopic hemostasis may be a significant factor either due to better experience or to the presence of more suitable for endoscopic hemostasis ulcers in the second period. The majority of rebleeding episodes occur in patients with duodenal ulcers and ulcers with active spurting bleeding during endoscopy both of which had been reduced in the second period. 26, 27 The percentage of patients with duodenal ulcer bleeding was reduced recently. Chronic duodenal ulcers in contrast to acute ulcers produce destruction of the duodenal bulb and erode deeper and larger vessels which bleed more severely and make endoscopic hemostasis difficult or even impossible.
Overall mortality rates in our patients in both periods in our area are lower in comparison with bleeding mortality rates described in previous studies 15 and compare favorably with the figures of 3.7% to 5% prospectively evaluated in some individual units. 13 The wide variation in bleeding mortality rates from 3% to 15% may partly be explained either by case selection or by the fact that many of these studies are undertaken in specialized centers. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] 15, 28 In our study we included all patients presenting with AUGIB in our area, both in university and nonuniversity hospitals. Almost half of our patients have none or mild coexisting diseases. In a study by Sandel et al 29 lower mortality was noticed among nonvariceal upper GI bleeding patients admitted to a gastroenterologic service compared with an internal medicine service and was mainly due to lower comorbidity in these patients.
Overall mortality rates and PUB mortality rates remained unchanged, although a trend toward higher overall mortality was observed recently. This trend of increased mortality is in accordance with the increase in the age of patients presenting with AUGIB, and the increase in the presence of severe comorbidity in our patients. Over two-thirds of deaths are not considered to be caused by the bleeding episode itself but by other reasons, because blood loss and emergency surgery is poorly tolerated by patients of increased age and/or with increased comorbidity. 28 However, rebleeding and need for emergency surgical hemostasis were lower in the second period and this reduction may counteract the increased deaths due to comorbidities.
In conclusion, the incidence of AUGIB seems to have been decreased, mainly due to the decline in the incidence of bleeding peptic ulcers. Despite AUGIB is presented at increasing age, with a higher incidence in patients aged over 75 and with higher comorbitity, rebleeding rates are reduced and mortality is not significantly increased.
